AMAL develops peptide/protein-based therapeutic vaccines based on a proprietary technology platform called KISIMA®

Collaboration opportunities


Through new research collaborations and partnerships with pharmaceutical and biotech companies as well as academia and clinics, we aim to fully leverage our KISIMA® based technology with cutting edge science and advance research and development in immuno-oncology.

Discuss collaboration opportunities Learn more about KISIMA®

Collaboration opportunities

We have signed an exclusive patent license agreement with the University of Minnesota and the University of Geneva for different components of KISIMA®.

We also have a research collaboration agreement with the University of Tübingen and ongoing collaborations with academic groups and KOLs to further explore the potential of our KISIMA® platform, including the Geneva University, the HUG (Hopitaux Universitaires de Genève), the Fox Chase Cancer Center, the Istituto Oncologico Veneto, and the MD Anderson Cancer Center.

You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL: